New Resubmission Policy at NIH

The National Institutes of Health is now allowing grant applicants to resubmit unsuccessful proposals as new.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, VALENTIN OTTONEWhile the National Institutes of Health (NIH) previously allowed those applying for research funds a chance to resubmit grant applications only once, last week (April 16) the agency announced that grant applicants that are unsuccessful a second time can resubmit again, this time as new, stand-alone proposals. The policy eliminates the need to show how the application has changed or responding to previous reviews for resubmission as a new application.

“While the new policy still allows a single resubmission per application, ideas that were unsuccessfully submitted as a resubmission (A1) may now be presented in a new grant application (A0) without having to substantially redesign the content and scope of the project,” NIH Deputy Director for Extramural Research Sally Rockey explained in an April 17 Rock Talk blog post. Moreover, she added, “reviewers will be instructed to review it as a new idea even if they have seen it in prior cycles.” Rockey noted, however, that applicants ought to consider previous reviews when submitting revised proposals in order to have the best possible chance of favorable grant reviews.

As ScienceInsider reported, in the increasingly tight funding climate the agency’s old policy had become “especially hard ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies